Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $87000.0.

  • Guided Therapeutics' Cash & Current Investments fell 5515.46% to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year decrease of 5515.46%. This contributed to the annual value of $388000.0 for FY2024, which is 3434.86% down from last year.
  • According to the latest figures from Q3 2025, Guided Therapeutics' Cash & Current Investments is $87000.0, which was down 5515.46% from $185000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Cash & Current Investments registered a high of $2.7 million during Q3 2022, and its lowest value of $87000.0 during Q3 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $591000.0 (2023), whereas its average is $828421.1.
  • As far as peak fluctuations go, Guided Therapeutics' Cash & Current Investments soared by 583809.52% in 2021, and later plummeted by 7974.96% in 2024.
  • Over the past 5 years, Guided Therapeutics' Cash & Current Investments (Quarter) stood at $643000.0 in 2021, then surged by 259.72% to $2.3 million in 2022, then tumbled by 74.45% to $591000.0 in 2023, then tumbled by 34.35% to $388000.0 in 2024, then tumbled by 77.58% to $87000.0 in 2025.
  • Its Cash & Current Investments was $87000.0 in Q3 2025, compared to $185000.0 in Q2 2025 and $115000.0 in Q1 2025.